Brief: Xintela Unit Selects Targ9 As Drug Candidate
05/04/2022 12:58
April 5 (Reuters) - Xintela AB XINT.ST :
* TARGINTA SELECTS ADC-ANTIBODY TARG9 AS DRUG CANDIDATE
* CANDIDATE, BEING DEVELOPED AGAINST TRIPLE-NEGATIVE BREAST
CANCER
AND GLIOBLASTOMA, NOW ENTERS PRECLINICAL DEVELOPMENT
Source text for Eikon: ID:nMFN5nj3nD
Further company coverage: XINT.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Xintela AB
See all newsBrief: Xintela To Raise SEK 30 Mln Via Convertible Loan From Flerie Invest
Advisory: Alerts on Xintela's phase I/IIa XSTEM results withdrawn
Brief: Xintela Q1 2026 Loss Before Tax SEK 11.8 Mln
Brief: Xintela Study Finds XSTEM Treatment Safe, Well Tolerated
Brief: Xintela Gets U.S. Patent For Xstem Treatment Of Difficult-To-Heal Wounds, Skin Defects